Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease

A. Benoit, J. Beran, JM. Devaster, M. Esen, O. Launay, G. Leroux-Roels, JE. McElhaney, L. Oostvogels, GA. van Essen, M. Gaglani, LA. Jackson, T. Vesikari, C. Legrand, F. Tibaldi, BL. Innis, W. Dewé,

. 2015 ; 2 (2) : ofv067. [pub] 20150514

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc15031285

Background.  To investigate the relationship between hemagglutinin-inhibition (HI) antibody levels to the risk of influenza disease, we conducted a correlate of protection analysis using pooled data from previously published randomized trials. Methods.  Data on the occurrence of laboratory-confirmed influenza and HI levels pre- and postvaccination were analyzed from 4 datasets: 3 datasets included subjects aged <65 years who received inactivated trivalent influenza vaccine (TIV) or placebo, and 1 dataset included subjects aged ≥65 years who received AS03-adjuvanted TIV (AS03-TIV) or TIV. A logistic model was used to evaluate the relationship between the postvaccination titer of A/H3N2 HI antibodies and occurrence of A/H3N2 disease. We then built a receiver-operating characteristic curve to identify a potential cutoff titer between protection and no protection. Results.  The baseline odds ratio of A/H3N2 disease was higher for subjects aged ≥65 years than <65 years and higher in seasons of strong epidemic intensity than moderate or low intensity. Including age and epidemic intensity as covariates, a 4-fold increase in titer was associated with a 2-fold decrease in the risk of A/H3N2 disease. Conclusions.  The modeling exercise confirmed a relationship between A/H3N2 disease and HI responses, but it did not allow an evaluation of the predictive power of the HI response.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031285
003      
CZ-PrNML
005      
20160309114747.0
007      
ta
008      
151005s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ofid/ofv067 $2 doi
035    __
$a (PubMed)26180823
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Benoit, Anne $u Institut de Statistique, Biostatistique et Sciences Actuarielles, Université Catholique de Louvain , Louvain-la-Neuve , Belgium.
245    10
$a Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease / $c A. Benoit, J. Beran, JM. Devaster, M. Esen, O. Launay, G. Leroux-Roels, JE. McElhaney, L. Oostvogels, GA. van Essen, M. Gaglani, LA. Jackson, T. Vesikari, C. Legrand, F. Tibaldi, BL. Innis, W. Dewé,
520    9_
$a Background.  To investigate the relationship between hemagglutinin-inhibition (HI) antibody levels to the risk of influenza disease, we conducted a correlate of protection analysis using pooled data from previously published randomized trials. Methods.  Data on the occurrence of laboratory-confirmed influenza and HI levels pre- and postvaccination were analyzed from 4 datasets: 3 datasets included subjects aged <65 years who received inactivated trivalent influenza vaccine (TIV) or placebo, and 1 dataset included subjects aged ≥65 years who received AS03-adjuvanted TIV (AS03-TIV) or TIV. A logistic model was used to evaluate the relationship between the postvaccination titer of A/H3N2 HI antibodies and occurrence of A/H3N2 disease. We then built a receiver-operating characteristic curve to identify a potential cutoff titer between protection and no protection. Results.  The baseline odds ratio of A/H3N2 disease was higher for subjects aged ≥65 years than <65 years and higher in seasons of strong epidemic intensity than moderate or low intensity. Including age and epidemic intensity as covariates, a 4-fold increase in titer was associated with a 2-fold decrease in the risk of A/H3N2 disease. Conclusions.  The modeling exercise confirmed a relationship between A/H3N2 disease and HI responses, but it did not allow an evaluation of the predictive power of the HI response.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Beran, Jiri $u Vaccination and Travel Medicine Centre , Poliklinika II , Hradec Králové , Czech Republic.
700    1_
$a Devaster, Jeanne-Marie $u GSK Vaccines , Rixensart , Belgium.
700    1_
$a Esen, Meral $u Institut für Tropenmedizin, Universitätsklinikum Tübingen , Germany.
700    1_
$a Launay, Odile $u Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin-Pasteur; Inserm, CIC 1417-REIVAC , Paris , France.
700    1_
$a Leroux-Roels, Geert $u Centre for Vaccinology , Ghent University and Hospital , Belgium.
700    1_
$a McElhaney, Janet E $u Alan M. McGavin Chair in Geriatrics Research, Department of Medicine , University of British Columbia , Vancouver , Canada.
700    1_
$a Oostvogels, Lidia $u GSK Vaccines , Rixensart , Belgium.
700    1_
$a van Essen, Gerrit A $u Julius Center for Health Sciences and Primary Care , University Medical Center Utrecht , The Netherlands.
700    1_
$a Gaglani, Manjusha $u Section of Pediatric Infectious Diseases, Baylor Scott and White Health , Texas A&M Health Science Center College of Medicine , Temple.
700    1_
$a Jackson, Lisa A $u Group Health Research Institute , Seattle, Washington.
700    1_
$a Vesikari, Timo $u Vaccine Research Center , University of Tampere , Finland.
700    1_
$a Legrand, Catherine $u Institut de Statistique, Biostatistique et Sciences Actuarielles, Université Catholique de Louvain , Louvain-la-Neuve , Belgium.
700    1_
$a Tibaldi, Fabian $u GSK Vaccines , Rixensart , Belgium.
700    1_
$a Innis, Bruce L $u GSK Vaccines , King of Prussia, Pennsylvania.
700    1_
$a Dewé, Walthère $u GSK Vaccines , Rixensart , Belgium.
773    0_
$w MED00188131 $t Open forum infectious diseases $x 2328-8957 $g Roč. 2, č. 2 (2015), s. ofv067
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26180823 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20160309114802 $b ABA008
999    __
$a ind $b bmc $g 1092161 $s 914411
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 2 $c 2 $d ofv067 $e 20150514 $i 2328-8957 $m Open forum infectious diseases $n Open Forum Infect Dis $x MED00188131
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Archiving options